The role of magnesium deficiency in cardiovascular and intestinal inflammation

William B. Weglicki, Iu Tong Mak, Joanna J. Chmielinska, Maria Isabel Tejero-Taldo, Andrei M. Komarov, Jay H. Kramer

Division of Experimental Medicine, Departments of Biochemistry and Molecular Biology, and Medicine (Cardiology), George Washington University Medical Center, Washington DC 20037, USA

Correspondence: W.B. Weglicki, MD, Division of Experimental Medicine, Rm 439B Ross Hall, Department of Biochemistry and Molecular Biology, George Washington University Medical Center, 2300 Eye St., N.W., Washington DC 20037, USA

<phywbw@gwumc.edu>

Abstract. Hypomagnesemia continues to cause difficult clinical problems, such as significant cardiac arrhythmias where intravenous magnesium therapy can be lifesaving. Nutritional deficiency of magnesium may present with some subtle symptoms such as leg cramps and occasional palpitation. We have investigated dietary-induced magnesium deficiency in rodent models to assess the pathobiology associated with prolonged hypomagnesemia. We found that neuronal sources of the neuropeptide, substance P (SP), contributed to very early prooxidant/proinflammatory changes during Mg deficiency. This neurogenic inflammation is systemic in nature, affecting blood cells, cardiovascular, intestinal, and other tissues, leading to impaired cardiac contractility similar to that seen in patients with heart failure. We have used drugs that block the release of SP from neurons and SP-receptor blockers to prevent some of these pathobiological changes; whereas, blocking SP catabolism enhances inflammation. Our findings emphasize the essential role of this cation in preventing cardiomyopathic changes and intestinal inflammation in a well-studied animal model, and also implicate the need for more appreciation of the potential clinical relevance of optimal magnesium nutrition and therapy.

Key words: Mg-deficient rodent model, substance P and substance P receptor, N-methyl-D-aspartate (NMDA) receptor/channel, neutrophil superoxide, neutral endopeptidase, endotoxin

Neuropeptide responses in experimental magnesium deficiency

Severe dietary Mg deficiency leads to diverse pathology in animal models: myocardial necrosis, neuromuscular hyperexcitability, arrhythmia, hyperirritability, erythema, hemorrhagic skin lesions, increased oxidative stress, and myocardial susceptibility to ischemia/reperfusion stress [1, 2] and significant systolic dysfunction [3]. Our early investigations with Mg deficient (MgD) rodents, led to the discovery that circulating levels of the pro-inflammatory neuropeptide, substance P (SP) [4, 5] were significantly elevated [6-8] within 3 days after initiating a diet (Harlan Teklad, Madison, WI) containing only 9% of Recommended Daily Allowance for Mg (100% RDA ≈ 500 mg/kg feed) [2, 9]. Calcitonin gene-related peptide was also elevated at this time, and probably emanated from sensory neuron fibers which are rich in both neuropeptides [10]. Our later studies indicated that SP may be inducing many of the inflammatory/oxidative events which eventually promote cardiomyopathy. These early and late pathological events are described in figure 1. The
acute stage release of SP during Mg deficiency may initiate the events that determine the early and late stage responses. Interestingly, rats placed on moderate MgD (40% RDA) and severe MgD (9% RDA) diets for 3 weeks exhibited proportionately elevated circulating SP levels that were 2.43- and 5.14-fold higher than Mg sufficient controls (MgS ≥ 100% RDA), respectively. Indeed our findings and those of others suggested that even moderate dietary Mg deficiency induced significant systemic inflammation: increases in PGE2 [11], circulating histamine [12], and erythema [13]. In addition to the elevated levels of SP, the neurokinin-1 (NK-1) receptor for SP is increasingly expressed during Mg deficiency. Multi-label flow cytometry was used for estimation of the SP receptor in peripheral neutrophils of rats using a multi-label FACS assay with different fluorophores. The circulating neutrophils from the early stage of severe Mg deficiency indicated a 2-fold elevation of the SP receptor (figure 2). These results are con-

Figure 1. Temporal sequence and interplay of pathologic events involving the neuronal, hematopoietic, gastrointestinal, and cardiovascular systems during acute and chronic stages of Mg deficiency, and which may lead to enhanced ‘cardiac inflammation at a distance’ and eventual myopathy and cardiac dysfunction.

Figure 2. Representative data showing substance P receptor (SPR) up-regulation in neutrophils of Mg deficient (MgD) rats. Whole blood samples from 2 wk Mg sufficient (MgS, left panel) and MgD (right) rats were analyzed by flow cytometry. A multi-label FACS assay using simultaneously 4 different fluorophores with a mixture of fluorophore-tagged anti CD3 (for T lymphocytes), CD45RA (B Lymphocytes), CD11b (neutrophils), and indirectly tagged SPR (3 μg/mL) were used during the analysis.
sistent with our observations that superoxide production in neutrophils from MgD rats was significantly activated during the early stage of the diet. Thus, both the elevated SP levels, coupled with increased expression of the SP receptor, amplified the oxidative stress during the early stage of Mg deficiency.

**N-methyl-D-aspartate (NMDA) Receptor and SP-mediated Pathobiology during Mg deficiency**

The NMDA receptor/channel complex is an important mediator of neuropeptide release. The NMDA channel is blocked by Mg$^{2+}$ in a voltage-dependent manner [14] and specific NMDA receptor/channel blockers are protective. For example, Dizocilpine (MK-801), a non-competitive NMDA receptor/channel blocker, prevented noise-mediated seizures [15, 16] and depressed the acoustic startle reflex [17] in MgD rats. The influence of NMDA receptor inhibition on neutrophil superoxide production in severe MgD rats was examined. The enriched blood neutrophil fractions displayed a 5.3 fold (p < 0.02) elevated basal superoxide production and pretreatment with MK-801 attenuated this superoxide response by 69%, p < 0.01 (figure 3). Neuronal localization revealed significant concentrations around blood vessels, and staining with PGP-9.5, a pan neuronal stain, demonstrated a rich perivascular innervation throughout cardiac tissue. Using serial sections to correlate neuronal regions with areas of SP distribution revealed substantial co-localization of SP and inflammation around vascular elements during Mg deficiency. The acute

**Figure 3.** Effect of NMDA receptor blockade (MK-801, 0.5 mg/kg/day, s.c.) on PMN (superoxide production) activity during 3 wks of severe MgD treatment. Whole blood PMNs were obtained using a modified ficoll hypaque reagent and a step-gradient centrifugation [18]. Basal and stimulated superoxide anion production was assayed in the absence or presence of 100 ng/mL phorbol myristate acetate plus 75 μM cytochrome c with or without 50 μg SOD. Superoxide production was estimated as SOD-inhibitable reduction of cytochrome c using the extinction coefficient: E$_{550}$ = 2.1X10$^4$M$^{-1}$cm$^{-1}$. Values are means ± SD from 3-5 rats/group.
stage elevation in circulating SP [18] may arise, in part, from C-fibers of the dorsal root ganglia [19]. These ganglia were isolated from early stage and late stage severe MgD rats where the SP staining intensity was substantially reduced; pre-treatment of these MgD rats with MK-801 prevented much of the loss in SP staining intensity during the early and late response stages. We concluded that SP depletion from the DRG was due to unblocking of the NMDA receptor channel during Mg deficiency leading to enhanced neuronal SP release [20]. Chronic Mg deficiency also produced significant cardiac apoptosis with significantly elevated caspase 3 enzyme activity [21]. The effect of MK-801 treatment during severe Mg deficiency on DNA fragmentation in rat cardiac tissue was also examined; 33% apoptotic nuclei were seen in severe MgD hearts, and MK-801 treatment significantly decreased the number of apoptotic nuclei by 40%. Thus, cardiac apoptosis was inhibited by NMDA receptor blockade, and is likely modulated by neuronal SP release.

Neutral Endopeptidase during Mg deficiency

In addition to neuronal release of SP during the acute stage, heightened elevations of SP during the early and late response stages of Mg deficiency may also involve inactivation of neutral endopeptidase (NEP), the principal proteolytic SP-degrading enzyme [22]. Other proteases (angiotensin converting enzyme, dipeptidyl aminopeptidase IV, amino-
peptidase M) may degrade SP, but only to a lesser extent [23]. NEP is a metalloprotease expressed by various tissues and cells, including heart, small intestine, kidney, brain, airway epithelium, vascular endothelium [24], neutrophils [25] and macrophages [26]. We found that NEP inactivation can lead to enhanced SP-mediated systemic inflammation during Mg deficiency [27]. Moreover, NEP can be a target of oxidative damage by circulating lipid peroxidation products (conjugated dienes, MDA-like materials) [28, 29], and during the late response stage of Mg deficiency, we showed that NEP activity was significantly depressed in circulating neutrophils (figure 4).

In addition to these studies, we used the NEP inhibitor, phosphoramidon, to investigate its effect on circulating SP levels in conjunction with changes in oxidative stress (circulating prostaglandin E2 [PGE2], RBC glutathione [GSH] loss, and neutrophil activation). During the acute stage of Mg deficiency we found a 7.5-fold elevation in SP versus MgS control, but after phosphoramidon treatment a further 2.45-fold increase in total SP was seen versus untreated Mg deficiency (figure 5). These findings supported the notion that NEP strongly influences SP bio-availability during Mg deficiency. It remains to be determined if similar reductions in NEP activity occur in other tissues. Phosphoramidon treatment of control rats produced no significant superoxide production, indicating that, in the absence of elevated SP, the basal activity of neutrophils remained unchanged.

**Figure 5.** Effect of the NEP inhibitor, phosphoramidon (PR: 5 mg/kg/day, s.c.) on plasma SP levels during week 1 of severe Mg deficiency. SP levels were determined using an ELISA kit from R&D Systems (Minneapolis, MN) [31]. The assay is a competitive binding technique in which sample SP competes with a fixed amount of horseradish-labeled SP for sites on a murine monoclonal antibody. Color development is inversely proportional to SP concentration and absorbance is read at 450 nm. Values were normalized to baseline and are means ± SE of 3-6 rats. To obtain total levels for week 1, time-courses were area integrated.
Intestinal inflammation in Mg deficiency

The gut is also richly innervated [32] and during Mg deficiency, the C-fibers may contribute to the early rise in plasma SP. Even during the acute stage of Mg deficiency, mucosal inflammation by neutrophils was evident, and pronounced infiltration occurred by the late response stage [33]. Our prior studies had shown elevations of TNF-α in MgD animals. Since endotoxin (lipopolysaccharide, LPS) is known to induce a systemic elevation of TNF-α [34] by stimulating cytokine secretion, we wondered whether elevated levels of LPS promoted the secretion of TNF-α in Mg deficiency. Our studies using Evan’s blue dye showed a dramatic increase (19-fold > control) in capillary leak of gut tissue harvested from severe MgD rats during the early response stage [33]. Indeed, we found significantly elevated plasma LPS in the late response stage of MgD rats and these elevated levels of LPS were significantly inhibited by treatment with SP receptor blockade (figure 6). We reported previously that in vivo SP receptor blockade (CP-96,345) in MgD rats significantly lowered plasma TNF-α levels during the early response stage [6]. Taken together, these findings indicate a role for SP in the elevations of both LPS and TNF-α during Mg deficiency.

Since endotoxin receptor (CD14) is known to be up-regulated in cells exposed to LPS, we used immunohistochemical staining to monitor the expression of this LPS receptor [35,36]. We found prominent CD14 positive macrophage-type cells in the intestine of severe MgD rats during the early response stage; we also observed enhanced CD14 receptor expression in the cardiac tissue. The importance of CD14 in LPS-induced responses was

**Figure 6.** Effect of extending exposure to 5 wks on plasma endotoxin (LPS) levels during severe Mg deficiency with or without neurokinin-1 (NK-1) receptor blockade (L-703,606; 0.5 mg/kg/day, s.c. pellet). Systemic endotoxemia was measured in blood samples obtained with endotoxin-free needles, syringes, and glassware, then diluted 1:10 in endotoxin-free water, and heated for 5 min to remove interfering plasma components. Endotoxin was determined using limulus amebocyte lysate [35]. A quantitative colorimetric “Pyrochrome” assay (Associates of Cape Cod, Woods Hole, MA) was performed in 96-well microplates and read at 540 nm using a plate reader (Versa max; Molecular Devices). The detection limit for “Pyrochrome” is 0.3 pg/mL. Values are means ± SE of 3-5 rats.
shown previously using transgenic mice over-expressing CD14 receptor [37], where the known cardio-depressant effects of LPS were dependent on this CD14 signaling [38]. These observed significant elevations in plasma LPS in MgD rats indicated that prolonged Mg deficiency results in increased intestinal permeability to bacterial products leading to increased circulating LPS, along with elevated endotoxin receptor expression in the heart; this CD14 elevation may further amplify the cardiomyopathy leading to eventual contractile dysfunction. Recently, we used trans-thoracic echocardiography to study cardiac contractility during severe Mg deficiency in rats. We found that significantly impaired diastolic function occurred during the early response stage, and systolic function (% ejection fraction) was significantly decreased during the late response stage [3]. We anticipate that prolonged exposure (> 7 weeks) to a moderate MgD diet will also lead to impaired cardiac function, based on our observations of depressed baseline contractility in perfused hearts from these animals [3].

In conclusion, the animal studies of dietary Mg deficiency indicate that an inflammatory process is triggered by neuronal release of SP which may affect cardiovascular and intestinal tissues. In the event that gut permeability is enhanced, endotoxemia may result in further systemic inflammatory responses. The clinical literature has documented that patients with congestive heart failure may have elevated endotoxin levels [39-40] and that hypomagnesemia [41] may also be present due to diuretic therapy and other concurrent disease processes. We suggest that some of the findings from animal studies of Mg deficiency may have some clinically relevant parallels and we submit that the careful assessment of Mg status in patients may indicate the need for more frequent oral and intravenous therapy with this important electrolyte.

Financial support and disclosure

Supported by NIH Grants: RO1 HL062282 and HL 065178.

None of the authors has any conflict of interest to disclose.

References


